Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly's (LLY) Q3 earnings beat estimates while sales miss. Shares drop in pre-market trading.

Lilly (LLY) Q3 Earnings Top Estimates, Sales Lag, Stock Down

Lilly (LLY) delivered earnings and revenue surprises of 3.50% and -1.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Eli Lilly (LLY) Surpasses Q3 Earnings Estimates

Eli Lilly (NYSE: LLY) reported third-quarter earnings of $1.48 per share, which beat the analyst consensus estimate of $1.40 by 5.71%.

Eli Lilly Reports Mixed Q3 Earnings, Raises Guidance

Alexion Pharma

Eli Lilly earnings beat Q3 views, but sales missed. Alexion Pharmaceuticals earnings and revenue topped.

Eli Lilly, Alexion Earnings Top Q3 Views, But Stocks Diverge

Eli Lilly & Co. LLY, +1.79% said Wednesday it had net income of $1.254 billion, or $1.37 a share, in the third quarter, up from $1.149 billion, or $1.12 a share, in the year-earlier period.

Eli Lilly tops profit estimates in latest quarter as revenue falls short

Biogen

Bristol-Myers

Celgene

Vertex Pharmaceuticals

Healthcare in particular is one such sector, with a number of large-cap biotechnology and pharmaceutical stocks enjoying fresh rallies.

5 Healthcare Stocks to Buy

Southern Company

The following large-cap/loyal payers announced dividends on Monday. They are also doing better than most of their peers and the S&P 500 index in terms of a higher forward dividend yield.

2 Large-Cap Stocks Announce Dividends.

Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.

Lilly's Pancreatic Cancer Candidate Fails in Phase III Study

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.

Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?

Eli Lilly and Co. LLY, +1.67% said Wednesday a late-stage trail of a treatment for pancreatic cancer did not meet its main goal of overall survival.

Eli Lilly says late-stage trial of pancreatic cancer treatment failed to meet its main goal of overall survival

Merck

Pfizer

These aren't the highest payouts in the industry, but they have the best chance to steadily climb.

3 Dividend-Paying Pharma Stocks to Buy Now

Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.

Lilly Gets FDA Approval for New Oral Tablets for Migraine

FDA approves Eli Lilly’d new migraine drug Reyvow.

FDA approves new Eli Lilly drug to 'resolve' migraine pain in two hours

Eli Lilly's Taltz achieves superiority over Tremfya in a head to head study based on the primary endpoint at week 12 with PASI 100 skin clearance.

Eli Lilly Shows Its Strength With Taltz In Positive Head To Head Study

Amgen

Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.

3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates

General Mills

Hartford Financial Services Group

Stock charts of LLY, HIG and GIS are moving into the midpoint of the week on the verge of major moves.
The post 3 Big Stock Charts for Wednesday: General Mills, Eli Lilly and Hartford Financial Services appeared first on InvestorPlace.

3 Big Stock Charts for Wednesday: General Mills, Eli Lilly and Hartford Financial Services

Eli Lilly and Co. (NYSE: LLY) announced some good news for people suffering moderate to severe plaque psoriasis when it presented at the Fifth Annual Maui Derm NP+PA Fall meeting.

Plaque Psoriasis Suffers May Have Better Option After Eli Lilly Study

Eli Lilly and Co. said Thursday it is voluntarily delisting from the Euronext Paris exchange, citing low trading volume, costs and administrative requirements.

Eli Lilly to voluntarily delist from Euronext Paris exchange

GlaxoSmithKline

Novo Nordisk

How Big Can This $8 Billion-Plus Diabetes Drug Class Get?

Eli Lilly announced that it had achieved positive results from a phase 1/2 study using the drug selpercatinib to treat RET fusion-positive non-small cell lung cancer.

Eli Lilly Throws Hat In The Ring For Lung Cancer Space, Takes Targeted Treatment Approach

AbbVie

AbbVie and Eli Lilly have both stumbled this year. Which of these top pharma stocks is better positioned for a rebound?

Better Buy:  AbbVie vs.  Eli Lilly

Broadcom

Chipotle

Fidelity National Information

Netflix

Procter & Gamble

Union Pacific

Goldman Sachs says that a select group of reasonably priced, high-ROE growth stocks will outperform.

9 High Return Stocks That Can Lead With Market Near Record Highs

AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.

AC Immune to Earn Milestone From Lilly for Alzheimer's Drug

ConocoPhillips

Walgreens

These blue chips are perfectly positioned to gain ground through the fourth quarter and into 2020.

3 Stocks to Buy in the Fourth Quarter

CHMP gives positive opinion to add cardiovascular risk reduction data from the REWIND outcomes study on the label of Lilly's (LLY) diabetes medicine, Trulicity.

News for Eli Lilly Stock (LLY)